好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Investigating the Role of the Exposome on Neuropathology and Biochemical Phenotypes in Alzheimer’s Disease
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
13-008
To assess the effects of exposome components in the severity of neuropathology and biochemical phenotypes of AD.

Individual environmental exposures, the exposome, can play an influential role in the development and progression of neurodegenerative diseases such as AD. We hypothesize that potentially modifiable risk factors of AD such as diabetes, hypertension, smoking, and alcohol consumption, in addition to the underexplored area deprivation index (ADI), could play a considerable role in severity of neuropathology and biochemical phenotypes of AD.

We evaluated 478 neuropathologically characterized AD donors, from the Mayo Clinic Brain Bank. 469 samples had available biochemical measures (APOE, Aβ40, Aβ42, tau, and phosphor-tau (Thr231)), collected across three isolated fractions (soluble (TBS), membrane-bound (TX), and insoluble (FA)) of the superior temporal gyrus. Exposome variables were extracted from the available records. Associations of ADI, diabetes, hypertension, smoking and alcohol with biochemical and neuropathology phenotypes were examined using linear regression, binary logistic regression and ordinal logistic regression models as appropriate given the nature of the outcome variable; all models were adjusted for age at death and sex.

Higher ADI levels representing neighborhoods with increased deprivation, were nominally associated with soluble levels of APOE (β=0.006, p=0.01), cerebral infarcts (β=0.02, p=0.04), and we identified a trend for vascular brain injury (β=0.02, p=0.06). Alcohol was associated with lower levels of membrane bound APOE (β=-0.23, p=0.04).  We also observed trends for increased insoluble tau (β=0.21, p=0.06) in patients with hypertension and higher membrane bound and lower insoluble APOE (β=0.27, p=0.06); (β=-0.28, p=0.06) in patients with diabetes.

Different components of the exposome impact levels of core AD proteins. Additional analyses in expanded cohorts to further explore the associations with neuropathology are ongoing. We expect that understanding how exposome impacts specific aspects of neurodegenerative diseases will provide key insights into underlying, potentially modifiable, mechanisms of disease.

Authors/Disclosures
Gabriela M. Garofalo, MD
PRESENTER
Dr. Garofalo has nothing to disclose.
Joseph S. Reddy, PhD Dr. Reddy has nothing to disclose.
Michael Heckman, MS Prof. Heckman has nothing to disclose.
Stephanie Oatman, PhD Dr. Oatman has nothing to disclose.
Xue Wang, PhD The institution of Dr. Wang has received research support from NIH. The institution of Dr. Wang has received research support from Mayo Clinic.
Ginna Yepez, MD Dr. Yepez has nothing to disclose.
Lindsey Kuchenbecker Lindsey Kuchenbecker has nothing to disclose.
Thuy Nguyen Mrs. Nguyen has nothing to disclose.
Melissa Murray, PhD (Mayo Clinic) Dr. Murray has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Avid Radiopharmaceuticals. The institution of Dr. Murray has received research support from National Institute on Aging. The institution of Dr. Murray has received research support from Alzheimer's Association. The institution of Dr. Murray has received research support from Chan Zuckerberg Initiative.
Dennis W. Dickson, MD (Mayo Clinic) Dr. Dickson has nothing to disclose.
Takahisa Kanekiyo, MD, PhD Dr. Kanekiyo has nothing to disclose.
Minerva Carrasquillo (Mayo Clinic Florida) The institution of Minerva Carrasquillo has received research support from NIA. The institution of Minerva Carrasquillo has received research support from Carl Angus DeSantis Foundation. The institution of Minerva Carrasquillo has received research support from Florida Department of Health. Minerva Carrasquillo has received personal compensation in the range of $500-$4,999 for serving as a Reviewer for Study Section with NIH.
Mariet Allen, PhD (Mayo Clinic) The institution of Dr. Allen has received research support from NIH. The institution of Dr. Allen has received research support from Florida Department of Health. Dr. Allen has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Nilufer Taner, MD, PhD, FAAN (Mayo Clinic) The institution of Dr. Taner has received research support from NIH.